Skip to main content
Equibles
HLYK logo

HLYK · HealthLynked Corp · Metrics

Track HLYK — free

Use HLYK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HLYK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.09 At close · Oct 16
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Without raising additional capital, there is substantial doubt about the Company's ability to continue as a going concern through August 14, 2027.”
View the 10-Q filed Aug 14, 2026
Market Cap
$6.17M
Shares
2.95M
Volume · Oct 16 1730 Avg daily vol (3M) 1178

HLYK metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.09
Market cap
$6.17M

Price action

20 metrics
Price change (1W)
-7.4%
Price change (30D)
-12.3%
Price change (3M)
-29.2%
Price change (6M)
-40.3%
Price change (YTD)
+49.1%
Price change (1Y)
+49.6%
Trailing year
Price change (5Y)
—
52-week high
$6.15
52-week low
$1.26
Change from 52-week high
-66.0%
Change from 52-week low
+65.7%
Annualized volatility
187.7%
Annualized volatility (3M)
—
Beta
-0.4
RSI (14D)
42.3
Price vs SMA 50
-20.8%
Price vs SMA 200
-21.7%
Avg volume (3M)
1,178
Relative volume
1.5
Average dollar volume
$2,994

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
2.95M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.5×
reciprocal yield 22.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-64.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-167.6%
Trailing 12 months
Net margin
-289.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$2.30M
Net income (TTM)
−$3.97M
Trailing 12 months
Diluted EPS (TTM)
$-1.38
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.48
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.80
EBITDA per diluted share (TTM)
$-0.77
Net income per diluted share (TTM)
$-1.37
Operating cash flow per diluted share (TTM)
$-0.50
Free cash flow per diluted share (TTM)
$-1.24
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.18
Book value per share
$-2.00

Growth

11 metrics
Revenue growth YoY
-57.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.4%
Year over year · more shares
Revenue CAGR (3Y)
-29.4%
Revenue CAGR (5Y)
-19.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-249.2%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$2.22M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$12,844
Total assets
$1.59M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.44M
Capital expenditures (TTM)
$2,598
R&D (TTM)
—
SG&A (TTM)
$2.32M
Stock compensation (TTM)
$531,992
R&D / revenue
—
Stock compensation / revenue
38.8%

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
0
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+0.0%
Holder tenure
23.0
Price vs estimated holder cost
-75.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
10 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1680139 CUSIP 42228P300 Visit website Investor relations